This breakthrough multiplexed assay supports the simultaneous detection of antibodies targeting multiple SARS-CoV-2 antigens.
The FlowMetric multiplex serology assay provides double the amount of information over the same testing time period compared to other existing assays run on ELISA and lateral flow platforms.
For vaccine development efforts, the novel FlowMetric assay can differentiate a clinical infection from a vaccine response. People immunized with the Spike(S) or Receptor-Binding Domain (RBD) protein will be positive for that antigen but negative on the Nucleocapsid (N) antigen, while those exposed to the actual virus will be positive on both.
If you would like to learn more about FlowMetric’s novel serology assay, please complete the form below and we will get back to you within 24 hours.
FlowMetric’s flow cytometry SARS-Cov-2 serology assay simultaneously detects antibodies that target two separate SARS-CoV-2 antigens:
the highly immunogenic
Nucleocapsid (N) protein
the Receptor-Binding Domain (RBD) portion of the Spike (S) protein, which is associated with neutralizing antibodies
The selection of these antigen regions specific to the SARS-CoV-2 virus has been demonstrated to minimize potential cross-reactivity with other viruses and therefore supports higher positive predictive values.
Compared to existing serology platforms, such as ELISA and lateral flow, the FlowMetric flow cytometry multiplex assay delivers equal or higher clinical sensitivity and specificity as well as a wider range of detection.
FlowMetric has developed and validated a
novel multiplexed SARS-CoV-2 serology assay
that offers outstanding performance, excellent sensitivity and exceptional specificity using a proven, high-throughput flow cytometry platform.
The applications of this breakthrough multiplexed assay are ideal for companies working on vaccine development or looking to identify modulation of SARS-CoV-2 antibodies in the development of therapeutic modalities.